GoAI
Get started
Cibus, Inc. logo

Cibus, Inc.

CBUS

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$1.74

+$0.04 · +2.35%

Aug 24, 12:09 PM ET

CBUS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

18

Overpriced

Momentum

67

Gaining

Sentiment

39

Bearish

Risk resilience

23

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Craig Wichner
Listed since
Jul 20, 2017
Employees
118

Market position

Day range

Current $1.74

52-week range

Current $1.74

Open
$1.66
Previous close
$1.70
Volume
33.15K
0.1× average
Average volume
330.2K
Average daily volume
Market cap
132.82M USD
Beta
1.62
Market reference 1
50-day average
$1.6908
+2.91% above average
200-day average
$1.8592
-6.41% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.05B USD
P/E (TTM)
-1.2×
P/B (TTM)
9.02×
P/S (TTM)
30.55×
EV / EBITDA
-11.61×
Earnings yield
-15.96%
Free cash flow yield
-6.43%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-90.52%
Operating margin
-1240.90%
Net margin
-2258.89%
Return on equity
-582.18%
Return on assets
-41.66%
Return on invested capital
-23.16%

Financial health

Debt / equity
2.21×
Current ratio
0.72×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1841%-5210%-12262%-19313%Gross margin, FY2021: -9.89%Gross margin, FY2022: -877.07%Gross margin, FY2023: 78.26%Gross margin, FY2024: -60.93%Gross margin, FY2025: -62.76%Operating margin, FY2021: -112.87%Operating margin, FY2022: -14248.41%Operating margin, FY2023: -17549.97%Operating margin, FY2024: -1805.82%Operating margin, FY2025: -1853.92%Net margin, FY2021: -112.36%Net margin, FY2022: -10758.60%Net margin, FY2023: -14729.06%Net margin, FY2024: -5898.36%Net margin, FY2025: -3492.31%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -9.89%. Gross margin FY2022 -877.07%. Gross margin FY2023 78.26%. Gross margin FY2024 -60.93%. Gross margin FY2025 -62.76%. Operating margin FY2021 -112.87%. Operating margin FY2022 -14248.41%. Operating margin FY2023 -17549.97%. Operating margin FY2024 -1805.82%. Operating margin FY2025 -1853.92%. Net margin FY2021 -112.36%. Net margin FY2022 -10758.60%. Net margin FY2023 -14729.06%. Net margin FY2024 -5898.36%. Net margin FY2025 -3492.31%.

Income trends

Revenue

3.64M USD-14.62%

Operating income

−67.46M USD+12.34%

Net income

−127.09M USD+49.45%
Income trends across reported periods60.47M USD−77.47M USD−215.42M USD−353.37M USDRevenue, FY2021: 25.99M USDRevenue, FY2022: 157K USDRevenue, FY2023: 1.82M USDRevenue, FY2024: 4.26M USDRevenue, FY2025: 3.64M USDOperating income, FY2021: −29.33M USDOperating income, FY2022: −22.37M USDOperating income, FY2023: −318.88M USDOperating income, FY2024: −76.96M USDOperating income, FY2025: −67.46M USDNet income, FY2021: −29.2M USDNet income, FY2022: −16.89M USDNet income, FY2023: −267.63M USDNet income, FY2024: −251.39M USDNet income, FY2025: −127.09M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 25.99M USD. Revenue FY2022 157K USD. Revenue FY2023 1.82M USD. Revenue FY2024 4.26M USD. Revenue FY2025 3.64M USD. Operating income FY2021 −29.33M USD. Operating income FY2022 −22.37M USD. Operating income FY2023 −318.88M USD. Operating income FY2024 −76.96M USD. Operating income FY2025 −67.46M USD. Net income FY2021 −29.2M USD. Net income FY2022 −16.89M USD. Net income FY2023 −267.63M USD. Net income FY2024 −251.39M USD. Net income FY2025 −127.09M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.64M USD4.26M USD1.82M USD157K USD25.99M USD
Cost of goods sold5.92M USD6.86M USD395K USD1.53M USD28.56M USD
Gross profit−2.28M USD−2.6M USD1.42M USD−1.38M USD−2.57M USD
Research and development44.2M USD50.43M USD42.37M USD11.55M USD11.34M USD
Selling, general, and administrative26.91M USD30.8M USD28.91M USD9.44M USD15.38M USD
Operating expenses65.18M USD74.37M USD320.31M USD20.99M USD26.76M USD
Interest income438K USD631K USD527K USD60K USD17K USD
Interest expense35.48M USD34.19M USD18.89M USD87K USD1.43M USD
Depreciation and amortization5.92M USD6.86M USD4.69M USD1.53M USD2.34M USD
Operating income−67.46M USD−76.96M USD−318.88M USD−22.37M USD−29.33M USD
Net income−127.09M USD−251.39M USD−267.63M USD−16.89M USD−29.2M USD

Company facts updated Aug 24, 2026.

CBUS news

seekingalpha.com

Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript

Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates

Cibus (CBUS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.61 per share a year ago.

Read source
marketbeat.com

Cibus Q2 Earnings Call Highlights

Cibus NASDAQ: CBUS reported second-quarter 2026 revenue of $1.0 million, compared with $0.9 million a year earlier, as the agricultural biotechnology company advanced its Sustainable Ingredients program and updated the…

Read source
globenewswire.com

Cibus Reports Second Quarter Financial Results and Provides Business Update

Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly net cash usage…

Read source
globenewswire.com

Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call

SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a technology company that helps farmers grow more food with fewer inputs, today announced that the company will report second quarter 2026…

Read source
globenewswire.com

Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus

Under new EU rules, crops improved without adding foreign DNA will be treated like conventionally bred crops, validating the approach Cibus has developed for 25 years Under new EU rules, crops improved without adding…

Read source

CBUS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.73

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.43

-0.47%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.21

+0.03%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.96

-0.49%

Sanofi logo

SNY

Sanofi

$45.6371

-0.46%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$824.47

-1.15%

Continue in GoAI

Research CBUS

research.disclaimer